RIGEL PHARMACEUTICALS INC

Explore Rigel Pharmaceuticals’ small‑molecule breakthroughs for blood cancers, immune disorders, and rare diseases, plus latest stock, market cap & valuation insights.

Rigel Pharmaceuticals names Dr. Alison Hannah, oncology veteran, as CMO to fast‑track R289 and vepdegestrant, boosting its cancer therapy pipeline and investor confidence.

Rigel Pharmaceuticals: market cap $481 M, low P/E, focus on hematologic, cancer, and rare immune disorders; navigating biotech volatility and patient‑care innovation.

Rigel Pharmaceuticals 2026 outlook: key milestones, market trends, and biopharma focus on hematologic, cancer, and rare immune diseases.

Rigel Pharmaceuticals’ breakthrough Phase 1b results boost investor confidence and elevate its stock, positioning the biotech firm for growth in hematologic and cancer therapies.

Rigel Pharmaceuticals Inc is a pioneering biotech company dedicated to developing innovative therapies for challenging medical conditions, with a strong financial foundation and promising growth prospects.